Aptamer Group Plc (APTA) Price & Analysis

Compare

11 Followers

APTA Stock Chart & Stats

0.80p

-0.01p(-2.86%)

At close: Jan 09 4:00 PM EST

0.80p

-0.01p(-2.86%)

Day’s Range― - ―

52-Week Range0.23p - 1.57p

Previous CloseN/A

Volume3.91M

Average Volume (3M)15.29M

Market Cap

£24.27M

Enterprise Value23.70M

Total Cash (Recent Filing)£1.06M

Total Debt (Recent Filing)£491.00K

Price to Earnings (P/E)―

Beta0.73

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding2,696,978,300

10 Day Avg. Volume14,821,052

30 Day Avg. Volume15,285,032

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)5.32

Price to Sales (P/S)6.11

P/FCF Ratio-3.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Niche Aptamer Technology And Structural DemandAptamer Group operates in a specialized biotech niche supplying custom aptamer discovery, products and partnership services. That diversified service/product model and stated growing demand for aptamer solutions support durable contract and milestone revenue potential and sustained industry relevance.

Improved Leverage ManagementAn improved debt-to-equity position indicates management has reduced leverage pressure, improving financial flexibility. Lower relative indebtedness strengthens the balance sheet and increases runway for R&D or commercialization initiatives if operating performance stabilizes.

Early Improvement In Free Cash Flow GrowthA modest uptick in free cash flow growth, even against negative operating cash flow, suggests initial progress on cash discipline or timing of receipts. If sustained, this can reduce reliance on external financing and support continued investment in discovery services and product development.

Bears Say

Severe Recent Revenue DeclineA near-total revenue collapse drastically erodes scale, limiting ability to cover fixed costs, invest in R&D, or maintain commercial programs. Such a structural drop risks lost customer relationships and makes recovery dependent on winning new contracts or re‑scaling operations.

Persistent Losses And Falling MarginsOngoing negative EBIT and net margins, plus declining gross margins, point to structural profitability challenges. Without margin recovery through pricing, cost control, or higher‑value contracts, the company’s ability to generate retained earnings and fund growth is constrained.

Negative Operating Cash Flow And Cash BurnNegative operating cash flow indicates core activities are consuming cash, forcing dependence on financing or milestone payments. Persistent cash burn undermines liquidity and the ability to sustain R&D and service delivery absent durable revenue recovery or external funding.

Aptamer Group Plc News

Aptamer Group hits key milestone in Metir pathogen detector collaboration

Aptamer Group Plc ( ($GB:APTA) ) has provided an announcement. Aptamer Group plc has completed Phase 1 of...

17d ago

Aptamer’s Optimer Tech Powers Twist Bioscience’s New TrueAmp NGS Library Prep Kit

Aptamer Group Plc ( ($GB:APTA) ) has shared an update. Twist Bioscience has launched its new TrueAmp Library...

23d ago

Aptamer Group Secures New Pharma Contracts and First Cash from Optimer Licensing

An announcement from Aptamer Group Plc ( ($GB:APTA) ) is now available. Aptamer Group has reported £190,000 of...

1M ago

Aptamer Group Reasserts Cash Runway to June 2027 Amid Media Speculation

Aptamer Group Plc ( ($GB:APTA) ) has issued an announcement. Aptamer Group plc issued a brief trading update...

2M ago

Aptamer Group lifts H1 revenue 27% as licensing push builds recurring income

Aptamer Group Plc ( ($GB:APTA) ) has shared an announcement. Aptamer Group reported a 27% year-on-year rise in...

2M ago

Aptamer Group Secures Second Enzyme-Modulation Licence with Alphazyme for Hot-Start PCR Optimer

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group has signed a non-exclusive worldwide OEM...

2M ago

Aptamer Group Partners with Twist Bioscience for NGS Market Expansion

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group plc has entered into a non-exclusive...

3M ago

Aptamer Group PLC Reports Strong Commercial Momentum and Strategic Progress

Aptamer Group Plc ( ($GB:APTA) ) has shared an update. Aptamer Group PLC has reported significant commercial momentum...

3M ago

Aptamer Group Secures Key Contracts, Strengthening Commercial Momentum

An announcement from Aptamer Group Plc ( ($GB:APTA) ) is now available. Aptamer Group plc has announced significant...

4M ago

Aptamer Group Secures Major Contract with Top Pharmaceutical Partner

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group has secured a significant new contract...

4M ago

APTA FAQ

What was Aptamer Group Plc’s price range in the past 12 months?

Aptamer Group Plc lowest share price was 0.23p and its highest was 1.57p in the past 12 months.

What is Aptamer Group Plc’s market cap?

Aptamer Group Plc’s market cap is £24.27M.

When is Aptamer Group Plc’s upcoming earnings report date?

Aptamer Group Plc’s upcoming earnings report date is Mar 26, 2026 which is in 20 days.

How were Aptamer Group Plc’s earnings last quarter?

Aptamer Group Plc released its earnings results on Oct 14, 2025. The company reported -0.001p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001p.

Is Aptamer Group Plc overvalued?

According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aptamer Group Plc pay dividends?

Aptamer Group Plc does not currently pay dividends.

What is Aptamer Group Plc’s EPS estimate?

Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aptamer Group Plc have?

Aptamer Group Plc has 2,696,978,300 shares outstanding.

What happened to Aptamer Group Plc’s price movement after its last earnings report?

Aptamer Group Plc reported an EPS of -0.001p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.111%.

Which hedge fund is a major shareholder of Aptamer Group Plc?

Currently, no hedge funds are holding shares in GB:APTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aptamer Group Plc

Aptamer Group Plc (APTA) is a biotechnology company that specializes in the development of novel aptamer-based technologies for various applications in diagnostics, therapeutics, and research. The company operates primarily in the life sciences sector, focusing on providing high-quality, synthetic aptamers—short, single-stranded oligonucleotides that can bind to specific target molecules. Aptamer Group's core products and services include the design and production of aptamers for use in pharmaceutical development, as well as tools for biomarker discovery and diagnostics.